PIONEER 5 The PIONEER 5 study enrolled patients with T2DM and moderate renal impairment (estimated glomerular filtration rate [eGFR] of 3059 mL/ min/1.73 m 2 ) to examine the efficacy and safety of oral semaglutide in patients with compromised kidney function
[DOI] [PMC free article] [PubMed] [Google Scholar] 39.Porter L.C., Franczyk M.P., Pietka T., Yamaguchi S., Lin J.B., Sasaki Y., Verdin E., Apte R.S., Yoshino J
The formula addresses multiple systems through gut health and botanicals, at a price point that's easier to sustain long-term
Our specialist team will conduct a comprehensive metabolic, hormonal, and longevity assessment to determine which GLP-1 therapy or combination of therapies is most appropriate for your individual health profile and goals